Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.

Prostate cancer and prostatic diseases - 1 Dec 2020

Ratta Raffaele, Guida Annalisa, Scotté Florian, Neuzillet Yann, Teillet Asmahane Benmaziane, Lebret Thierry, Beuzeboc Philippe

Abstract excerpt

BACKGROUND: A great number of DNA-damage repair (DDR) pathways have been recognized to be frequently dysregulated in advanced stages of prostate cancer. DNA-repair defects in prostate cancer represents a clinically relevant disease subset. Tumors whose ability to repair double-strand DNA breaks by homologous recombination is compromised, are highly sensitive to blockade of the repair of DNA single-strand breaks...

Topics

BRCA1 Protein
BRCA2 Protein
Clinical Trials as Topic
Humans
Male
Mutation
Neoplasm Metastasis
Poly(ADP-ribose) Polymerase Inhibitors
Prostatic Neoplasms
Randomized Controlled Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Survival Rate

Treatment Outcome

Source

Identifiers

PMID: 32367009
DOI: 10.1038/s41391-020-0233-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.PMID 32367009Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.Semantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Semantic proximity Read ↗

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsSemantic proximity Read ↗

Advances in PARP Inhibitors for Prostate CancerSemantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity Read ↗

The emerging role of PARP inhibitors in prostate cancer.Semantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancerSemantic proximity Read ↗

PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.